Novo Nordisk’s Wegovy Breakthrough: Weight-Loss Drug Shows Remarkable Heart Benefits, Paving the Way for Insurance Revisions
The study, presented at a medical conference, revealed a 20% decline in the risk of heart attack and stroke among patients categorized as “overweight” or “obese” based on their body mass index (BMI). Novo Nordisk’s Wegovy has demonstrated significant potential in reducing the risk of recurring heart attacks and strokes in individuals with pre-existing cardiovascular … Read more